

Dkt. 0575/51917-CA-PCT-US/JPW/JCS

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants David J. Pinsky, et al.

U.S. Serial No.: 10/679,135 Examiner: J. Pak

Filed October 3, 2003 : Art Unit: 1616

For A METHOD FOR TREATING ISCHEMIC DISORDER USING

CARBON MONOXIDE

1185 Avenue of the Americas New York, New York 10036

August 11, 2006

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Supplemental Information Disclosure Statement is submitted to supplement the Information Disclosure Statements filed October 3, 2003; June 15, 2004; September 16, 2004; December 30, 2004; and April 10, 2006. In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following references which are also listed on the attached Form PTO-1449 attached hereto as Exhibit A.

- 1. Ryter, S.W. and Choi, A.M., "Therapeutic applications of carbon monoxide in lung disease" Current Opinion Pharmacology 6:257-262 (2006), a copy of which is attached as Exhibit B hereto;
- 2. Mayr, F.B., et al., "Effects of Carbon Monoxide Inhalation during Experimental Endotoxemia in Humans" Am. J. Respir.

08/14/2006 AKELECH1 00000057 10679135 re Med. 171:354-360 (2005), a copy of which is 01 FC:1806 180.00 OP

Applicants: David J. Pinsky, et al.

U.S. Serial No.: 10/679,135

Filed: October 3, 2003

Page 2

Exhibit C hereto; and

3. Dolinay, T. et al., "Can Inhalation Carbon Monoxide Be Utilized As A Therapeutic Modality In Human Diseases?" Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring, edited by Amann, A. and Smith, D., pages 203-236 (2005), a copy of which is attached as **Exhibit D** hereto.

Applicants request that the Examiner consider these references, initial the attached Form PTO-1449 and make the references of record in the subject application.

No fee, other than the \$180.00 fee for filing an Information Disclosure Statement under 37 C.F.R. §1.17(p), is deemed necessary in connection with the filing of this Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Applicants: David J. Pinsky, et al. U.S. Serial No.: 10/679,135

Filed: October 3, 2003

Page 3



If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

Respectfully submitted,

hereby certify that correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Jdhn P. White Reg. No. 28,678 Date

John P. White Registration No. 28,678 Attorney for Applicant Cooper & Dunham LLP 1185 Avenue of the Americas New York, New York 10036 (212) 278-0400

Fo rm PT	O-144	U.S. Department of Commerce	Application Number	10/679,135	
		Patent and Trademark Office	Filing Date	October 3, 200)3
		OLAK	First Named Inventor	David J. Pinsk	y, et al.
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Art Unit 1616 Examiner Name John Pal				1616	
				John Pak	
		s if necessary)	Attorney Docket No.	51917-CA-PC US/JPW/JCS	Т-
······································		NON PATENT LITERATURE DO	CUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of titem (book, magazine, journal, serial, symposium, catalog, etc. publisher, city and/or country when) date, page(s), volume-iss		T ²
		Ryter, S.W. and Choi, A.M., "Thera		tions of	~~~~~~~~~~
ľ		carbon monoxide in lung disease	" Current Op:	inion on	
		Pharmacology 6:257-262 (2006)		<u> </u>	
		Mayr, F.B., et al., "Effects of Car			
1		during Experimental Endotoxemia in Humans" Am. J. Respir. Crit Care Med. 171:354-360 (2005)			
	Dolinay, T. et al., "Can Inhalation Carbon Monoxide Be				
	Utilized As A Therapeutic Modality In Human Diseases?" Breath Analysis for Clinical Diagnosis and Therapeutic				
i					
		Monitoring, edited by Amann, A. and			
		236 (2005),			
ŀ					
			<u> </u>		
l				l	
				-	
				į	
				· · · · · · · · · · · · · · · · · · ·	
					·
					
ŀ				ļ	
ĺ				l	
				1	
				ļ	
				1	
				Ì	
				l	
		<u> </u>		1	
EXAMINEI		DATE CONSIDERED			

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'Applicant is to place a checkmark here if English language Translation is attached.

Applicants: David J. Pinsky et al. Serial No.: 10/679,135

Filed: October 3, 2003

Exhibit A